Related Experiment Video
Updated: Nov 20, 2025

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells
Published on: August 7, 2021
Targeting prenylation inhibition through the mevalonate pathway
Pimyupa Manaswiyoungkul1, Elvin D de Araujo2, Patrick T Gunning2,1
1Department of Chemistry , University of Toronto , 80 St. George Street , Toronto , Ontario M5S 3H6 , Canada.
Abstract:
Protein prenylation is a critical mediator in several diseases including cancer and acquired immunodeficiency syndrome (AIDS). Therapeutic intervention has focused primarily on directly targeting the prenyltransferase enzymes, FTase and GGTase I and II. To date, several drugs have advanced to clinical trials and while promising, they have yet to gain approval in a medical setting due to off-target effects and compensatory mechanisms activated by the body which results in drug resistance. While the development of dual inhibitors has mitigated undesirable side effects, potency remains sub-optimal for clinical development. An alternative approach involves antagonizing the upstream mevalonate pathway enzymes, FPPS and GGPPS, which mediate prenylation as well as cholesterol synthesis. The development of these inhibitors presents novel opportunities for dual inhibition of cancer-driven prenylation as well as cholesterol accumulation. Herein, we highlight progress towards the development of inhibitors against the prenylation machinery.
Insights
Protein prenylation is key in diseases like cancer and AIDS. Targeting upstream enzymes offers a new strategy to inhibit prenylation and cholesterol synthesis, potentially overcoming drug resistance.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Protein prenylation is a crucial biological process implicated in diseases such as cancer and AIDS.
- Current therapies targeting prenyltransferase enzymes (FTase, GGTase I/II) face challenges including off-target effects, drug resistance, and suboptimal potency.
Purpose of the Study:
- To explore an alternative therapeutic strategy by targeting upstream mevalonate pathway enzymes (FPPS, GGPPS).
- To investigate the potential of dual inhibition of prenylation and cholesterol synthesis for improved therapeutic outcomes.
Main Methods:
- Review of current research on prenylation inhibitors.
- Analysis of the mevalonate pathway and its key enzymes (FPPS, GGPPS).
- Discussion of novel inhibitor development strategies.
Main Results:
- Direct targeting of prenyltransferase enzymes has shown limited clinical success due to resistance and side effects.
- Inhibiting upstream enzymes (FPPS, GGPPS) offers a dual approach to block prenylation and cholesterol synthesis.
- This alternative strategy presents opportunities to overcome existing therapeutic limitations.
Conclusions:
- Targeting FPPS and GGPPS represents a promising avenue for developing novel therapeutics against cancer and AIDS.
- Dual inhibition of prenylation and cholesterol synthesis may offer enhanced efficacy and overcome drug resistance mechanisms.
- Further development of inhibitors against the prenylation machinery is warranted.
Related Concept Videos
Inhibition of Cdk Activity
Mitochondrial Precursor Proteins
Most of the mitochondrial...
Feedback Inhibition
Biosynthesis of Nucleic Acids
Regulation of Nuclear Protein Sorting
Enzyme Inhibition

